Atlas Trials

Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

Clinical trial NCT03474029 · RECRUITING

Trial details

NCT number
NCT03474029
Sponsor
Centers for Disease Control and Prevention
Status
RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Latent Tuberculosis
Start date
2019-08-01
Primary completion
2029-12-31
Enrollment
3400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.